Literature DB >> 7656232

Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma.

S Kabir1, G A Daar.   

Abstract

The possible role of inflammation-associated cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) was investigated by measuring the levels of these cytokines in serum samples from 21 patients with advanced gastric carcinoma. These values were compared with those detected in 17 age-matched controls. The levels of IL-1 beta and IL-6 were significantly increased (approximately sixfold) in gastric cancer patients. While there was a modest increase (approximately twofold) in the level of IL-1 alpha, the circulating level of TNF-alpha was greatly reduced (approximately threefold) in the patient group.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656232     DOI: 10.1016/0304-3835(95)03895-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

Review 1.  Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?

Authors:  Hironori Tsujimoto; Satoshi Ono; Takashi Ichikura; Yusuke Matsumoto; Junji Yamamoto; Kazuo Hase
Journal:  Gastric Cancer       Date:  2010-12-03       Impact factor: 7.370

2.  Systemic cytokine levels and subsequent risk of gastric cancer in Chinese Women.

Authors:  Hui-Lee Wong; Charles S Rabkin; Xiao-Ou Shu; Ruth M Pfeiffer; Qiuyin Cai; Bu-Tian Ji; Gong Yang; Hong-Lan Li; Nathaniel Rothman; Yu-Tang Gao; Wei Zheng; Wong-Ho Chow
Journal:  Cancer Sci       Date:  2011-08-10       Impact factor: 6.716

3.  Interleukin-1alpha concentration in tumors as a risk factor for liver metastasis in gastric cancer.

Authors:  Y Furuya; T Ichikura; H Mochizuki
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

4.  Efficacy of Omega Fatty Acid Supplementation on mRNA Expression Level of Tumor Necrosis Factor Alpha in Patients with Gastric Adenocarcinoma.

Authors:  Asghar Hosseinzadeh; Seyed Mojtaba Mohaddes Ardebili
Journal:  J Gastrointest Cancer       Date:  2016-09

5.  Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.

Authors:  Yuki Orikawa; Hiroki Kato; Koichi Seto; Nobuyoshi Kobayashi; Koji Yoshinaga; Hiroki Hamano; Yuko Hori; Tim Meyer; Mineo Takei
Journal:  Mol Pain       Date:  2010-10-28       Impact factor: 3.395

6.  IL-32 expression is an independent prognostic marker for gastric cancer.

Authors:  Sumiya Ishigami; Takaaki Arigami; Yasuto Uchikado; Tetsuro Setoyama; Yoshiaki Kita; Ken Sasaki; Hiroshi Okumura; Hiroshi Kurahara; Yuko Kijima; Aya Harada; Shinichi Ueno; Shoji Natsugoe
Journal:  Med Oncol       Date:  2013-03-12       Impact factor: 3.064

7.  Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer.

Authors:  Kayhan Erturk; Didem Tastekin; Murat Serilmez; Elif Bilgin; Hamza Ugur Bozbey; Sezai Vatansever
Journal:  Tumour Biol       Date:  2015-07-29

8.  C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer.

Authors:  Nevin Ilhan; Necip Ilhan; Yavuz Ilhan; Handan Akbulut; Mehmet Kucuksu
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

9.  IMMUNOBIOLOGICAL MONITORING OF VARIOUS GASTROINTESTINAL AND PRIMARY HEPATIC MALIGNANCIES.

Authors:  G S Chopra; K B Mishra; L S Vohra; M P Jaiprakash; J R Bhardwaj
Journal:  Med J Armed Forces India       Date:  2017-06-26

10.  Preoperative thrombocytosis predicts poor survival in patients with glioblastoma.

Authors:  Marc A Brockmann; Alf Giese; Kathrin Mueller; Finjap Janvier Kaba; Frank Lohr; Christel Weiss; Stefan Gottschalk; Ingo Nolte; Jan Leppert; Jochen Tuettenberg; Christoph Groden
Journal:  Neuro Oncol       Date:  2007-05-15       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.